Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease
NCT ID: NCT02060565
Last Updated: 2023-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2014-02-28
2034-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening for Chronic Liver Diseases in General Population
NCT06366425
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
NCT06814600
Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study
NCT00629421
Observational Clinical Study of the Natural Course and Long-term Prognosis of Patients With Chronic Liver Disease
NCT05653830
Non-invasive Methods for Predicting Decompensation of Chronic Liver Disease
NCT06741904
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic liver disease
all patients with chronic liver disease followed using non-invasive methods
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic hepatitis B
* alcohol liver disease
* non alcoholic liver disease
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Association HGE CHU Bordeaux Sud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juliette Foucher, MD
Role: STUDY_CHAIR
Association HGE CHU Bordeaux Sud
Faiza Chermak, MD
Role: STUDY_CHAIR
Association HGE CHU Bordeaux Sud
Victor de Lédinghen, MD, PhD
Role: STUDY_DIRECTOR
Association HGE CHU Bordeaux Sud
Jean-Baptiste Hiriart, MD
Role: STUDY_CHAIR
Association HGE CHU Bordeaux Sud
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre d'Investigation de la Fibrose hépatique Service Hépato-Gastroentérologie Hopital Haut-Lévèque
Pessac, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HL V-0214
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.